Fig. 1: Predicted average plasma concentration-time profiles of different doses of oral aripiprazole and their therapeutic-equivalent long-acting injectable (LAI) doses in pregnancy within one dosing interval at steady-state. | npj Women's Health

Fig. 1: Predicted average plasma concentration-time profiles of different doses of oral aripiprazole and their therapeutic-equivalent long-acting injectable (LAI) doses in pregnancy within one dosing interval at steady-state.

From: Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics

Fig. 1

a 15 mg oral dose in the second trimester, b 15 mg oral dose in the third trimester, c 20 mg oral dose in the second trimester, d 20 mg oral dose in the third trimester e 300 mg LAI dose in the second trimester, f 300 mg LAI dose in the third trimester, g 400 mg LAI dose in the second trimester, h 400 mg LAI in the third trimester. ARI is aripiprazole, PO is oral, LAI is long-acting injectable, mAUC maternal area under the plasma concentration-time curve under one dosing interval, fAUC foetal area under the plasma concentration-time curve under one dosing interval, mCmax maternal maximum concentration at steady-state, fCmax foetal maximum concentration at steady state, fAUC/mAUC foetal to maternal AUC ratio.

Back to article page